The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Cancer Diagnostics Market?
The cancer diagnostics market has expanded swiftly in recent years. It is projected to expand from $25.5 billion in 2025 to $28.58 billion in 2026, registering a compound annual growth rate (CAGR) of 12.1%. Historically, this growth was driven by several factors, including rising global cancer prevalence, increased investments in oncology research, the expansion of hospital diagnostic infrastructure, the growing adoption of imaging-based cancer detection, and improvements in laboratory automation.
The cancer diagnostics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $44.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. This projected growth during the forecast timeframe stems from factors such as the escalating demand for individualized cancer treatments, the growing embrace of next-generation sequencing diagnostics, the broadening of cancer screening initiatives across populations, increased funding for AI-driven oncology diagnostics, and ongoing breakthroughs in tests designed for multi-cancer detection. Key trends anticipated throughout this period encompass the growing uptake of molecular and companion diagnostics, the increasing incorporation of AI in identifying cancer, the wider application of biomarker-driven testing, the expansion of advanced high-throughput diagnostic platforms, and a heightened emphasis on early detection in cancer screening.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2570&type=smp
What Key Growth Drivers Are Influencing The Cancer Diagnostics Market?
Future expansion of the cancer diagnostics market is anticipated to be driven by increasing healthcare spending. This spending represents the aggregate financial outlay by governments, companies, and individuals on various healthcare services such as medical procedures, hospital stays, pharmaceuticals, and public health programs. The heightened need for healthcare funding stems from the growing occurrence of chronic illnesses, which necessitate expensive and extended care. Increased healthcare investment improves cancer diagnostics by promoting the use of sophisticated screening tools and broadening the availability of early detection options. This also leads to more accurate diagnoses through significant investment in contemporary equipment and dedicated laboratories, facilitating prompt treatment and superior patient results. For example, data released in May 2024 by the UK’s Office for National Statistics indicated that total healthcare expenditure experienced a 5.6% nominal increase in 2023, marking a 0.9% growth over 2022 levels. Consequently, the expanding healthcare expenditure is a key factor propelling the growth of the cancer diagnostics market.
Which Segment Groups Define The Cancer Diagnostics Market Landscape?
The cancer diagnostics market covered in this report is segmented –
1) By Products: Companion Diagnostics, Molecular Diagnostics
2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
Subsegments:
1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics,
2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics
What Trends Are Affecting The Cancer Diagnostics Market Dynamics?
Major companies operating in the cancer diagnostic device market are focusing on developing artificial intelligence (AI) technology, such as QAi Prostate, to gain a competitive advantage. QAi Prostate functions as a cancer diagnostic device for prostate cancer detection. For instance, in March 2023, Qritive, a Singapore-based company that creates AI-powered diagnostic tools for pathologists, introduced QAi Prostate. QAi Prostate is an advanced AI-powered instrument for prostate cancer diagnosis. It utilizes machine learning algorithms to accurately identify and classify both malignant and benign areas within prostate tissue samples. This tool is designed to assist pathologists in detecting prostate cancer and differentiating between malignant and benign regions in prostate tissue samples.
Which Companies Are Influencing The Cancer Diagnostics Market?
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics
Access The Complete Cancer Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Which Geographic Region Represents The Largest Cancer Diagnostics Market Share?
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Cancer Diagnostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=2570&type=smp
Browse Through More Reports Similar to the Global Cancer Diagnostics Market 2026, By The Business Research Company
Oncology Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model